14

Jun2018
On June 13, 2018, after considerable time in development, the pCPA released its Brand Process Guidelines for external feedback. The pCPA is interested in receiving feedback from all sectors with a stake in the negotiation process: brand and generic pharmaceutical companies, patient organizations, and other interested parties. The guidance documents, which ... Read More

04

May2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30th, 2018:  46 negotiations are currently underway with 7 new files added since the last update of March 31st, 2018: Adlyxine (lixisenatide): Used to treat type 2 diabetes mellitus Ilaris (canakinumab): Used ... Read More

12

Apr2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2018: 40 negotiations are currently underway with 4 new files added since the last update of February 28, 2018: Darzalex (daratumumab): Used to treat multiple myeloma Fiasp (insulin aspart): Used to ... Read More

29

Mar2018
Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018 In January 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) announced a five-year agreement that will reduce drug prices for all Canadians who use prescription generic drugs, participating public drug plans, and employee ... Read More

08

Feb2018
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of January 31, 2018: 35 negotiations are currently underway with 2 new files added since the last update of December 31, 2017: Spinraza (nusinersen): Used to treat 5q Spinal Muscular Atrophy Victoza (liraglutide): Used ... Read More

07

Dec2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of November 30, 2017: 39 negotiations are currently underway with 4 new files added since the last update of October 31, 2017: Cerdelga (eliglustat): Used to treat Gaucher disease Cerezyme (imiglucerase): Used to treat ... Read More

08

Nov2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of October 31, 2017: 46 negotiations are currently underway with 2 new files added since the last update of September 30, 2017: Gazyva (obinutuzumab): Used to treat follicular lymphoma Lynparza (olaparib): Used to treat ... Read More

11

Oct2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2017:  51 negotiations are currently underway with 6 new files added since the last update of August 31, 2017: Fibristal (ulipristal acetate): Used to treat uterine fibroids (2nd cycle pre-surgery) Glatect ... Read More

11

Sep2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of August 31, 2017:        47 negotiations are currently underway with 6 new files added since the last update of July 31, 2017: Brilinta (ticagrelor): Used with ASA to prevent atherothrombotic events with history ... Read More

09

Aug2017
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of July 31, 2017:  46 negotiations are currently underway with 7 new files added since the last update of June 30, 2017: Cinqair (reslizumab): Used to treat severe eosinophilic asthma Giotrif (afatinib): Used to ... Read More